United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 2, 2004 Centrex Inc. (Exact name of registrant as specified in its charter) Oklahoma 0-26915 73-1554121 (State or Other (Commission File (I.R.S. Employer Jurisdiction Number) Identification No.) of Incorporation) 9202 South Toledo Avenue Tulsa, Oklahoma 74137 (Address of principal executive offices including zip code) (918) 494-2880 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Item 5. Other Events and Regulations FD Disclosure. The Company is not participating in the formation of a subsidiary, Early Warning Technologies, Inc., with the California based Trifocal Group. The development of the Centrex Single Molecule Nucleic Acid Detection (SMD) technology will remain within the sole purview of Centrex, Inc. On March 2, 2004, the Company issued a press release, a copy of which is filed herewith as Exhibit 99.1 and incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (a) Exhibits 99.1 Press Release of Centrex Inc., dated March 2, 2004. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Centrex, Inc. (Registrant) Dated: March 3, 2004 By:/s/ Thomas R. Coughlin, Jr. --------------------------- Thomas R. Coughlin, Jr. President INDEX TO EXHIBITS Exhibit Number Description _____________ ___________________________________________________________ 99.1 Press Release of Centrex Inc., dated March 2, 2004.